NDAORALTABLET, FOR SUSPENSION
Approved
Dec 2023
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ABACAVIR SULFATE AND LAMIVUDINE (abacavir sulfate; lamivudine) by Matrix Surgical USA is mechanism of action: abacavir is a carbocyclic synthetic nucleoside analogue. Approved for hiv-1 infection. First approved in 2023.
Drug data last refreshed 19h ago
Mechanism of Action
Mechanism of Action: Abacavir is a carbocyclic synthetic nucleoside analogue. Abacavir is converted by cellular enzymes to the active metabolite, carbovir triphosphate (CBV-TP), an analogue of deoxyguanosine-5′-triphosphate (dGTP). CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT)…
Indications (1)
Worked on ABACAVIR SULFATE AND LAMIVUDINE at Matrix Surgical USA? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.